Biomatters’ US focus drives over 50% sales increase during 2011

Share Article

Increasing uptake of Biomatters flagship product, Geneious, by customers worldwide has driven a more than 50% increase in Biomatters’ sales revenue for 2011. More than half this growth has taken place in the US market as a result of recently opening offices on both the east and west coasts of the USA.

During 2012 we plan to further the size and reach of our US team, while also turning our attention to Europe where we have already established a rapidly growing customer base out of our NZ operations.

Biomatters’ Chief Operating Officer Quentin Christie says: “Our sales have grown in the last quarter of 2011 to three times that of the same period two years ago. A large part of this growth has been due to the demand by researchers for our Geneious software at the divisional and enterprise level, supporting research collaboration.”

Geneious is a bioinformatics software platform that enables researchers to search, organize and analyze genomic data using a single desktop program. The Geneious brand is now a registered trademark in the United States, Europe, Singapore, Australia, Switzerland and New Zealand.

The success of the software was recognized by Biomatters recently being placed in the Deloitte Fast 50 index of New Zealand’s fastest growing businesses for the second year running. At the end of last year Biomatters was also ranked among the top 10 “hot emerging companies” in the New Zealand Technology Investment Network’s annual survey of technology businesses.

“We are continuing to re-invest profits into the ongoing future growth of our business, with a 45% increase in our employee numbers in the past year,” says Biomatters’ Managing Director Dr. Brett Ammundsen. “During 2012 we plan to further the size and reach of our US team, while also turning our attention to Europe where we have already established a rapidly growing customer base out of our NZ operations.”

“We also have a number of new product enhancements in our development pipeline , targeted at the growing needs of our customer base to work with high throughput genomic data sets,” added Dr. Ammundsen.

The popularity of Geneious is due to its ability to simply render complex DNA, RNA and protein sequence information. This is reflected in a robust growth in the number of times Geneious is cited in scientific research publications worldwide. Geneious was cited in scientific literature over 800 times in 2011 - more than double the previous year - cementing its position as a top choice for researchers in biology and medicine.

About Biomatters Limited:
Biomatters, the creator of Geneious, is a privately held company headquartered in New Zealand with offices in New Jersey and San Francisco. Biomatters exports to over 80 countries and boasts a rapidly growing customer base with 50% of sales in the US.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Melissa Pentecost
Visit website

Media